Corcept Therapeutics Q2 2020 Earnings Report
Key Takeaways
Corcept Therapeutics reported a revenue of $88.6 million for the second quarter of 2020, a 23% increase compared to the same period in 2019. The company's GAAP diluted net income per share was $0.23, and non-GAAP diluted net income per share was $0.32. They reaffirmed their 2020 revenue guidance of $355 – 375 million.
Revenue of $88.6 million, a 23 percent increase from second quarter 2019
GAAP diluted net income of $0.23 per share, compared to $0.17 per share in second quarter 2019
Non-GAAP diluted net income of $0.32 per share, compared to $0.25 per share in second quarter 2019
Cash and investments of $409.6 million, compared to $349.0 million at March 31, 2020
Corcept Therapeutics
Corcept Therapeutics
Forward Guidance
Corcept Therapeutics reaffirms its 2020 revenue guidance of $355 - $375 million, expecting countervailing forces from the pandemic to continue in the coming quarters but remain manageable.